Observational studyFrontiers in immunology2025

Combination immunotherapy and anti-angiogenic therapy shows promising efficacy in NSCLC patients with recurrent or refractory brain metastases and negative driver genes.

Liwei Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.